p97 Inhibition for Broad-Spectrum Coronavirus Replication Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections, such as COVID-19, are limited, with only one FDA-approved drug, remdesivir, and no broad-spectrum therapeutic agents to effectively inhibit virus replication and infection.
Innovation Solution
Inhibiting the AAA+ ATPase p97 protein, which is crucial for viral replication by using agents like nucleic acid molecules, small molecule inhibitors, or genetic tools to reduce the expression of viral proteins and disrupt the viral life cycle.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If remdesivir is used to treat coronavirus infections, then viral replication is inhibited to some extent, but it is the only FDA-approved drug and lacks broad-spectrum effectiveness
Solution Approach 1:
The patent targets p97, a highly conserved host protein essential for viral replication across multiple coronavirus types. By inhibiting p97, the therapy can effectively treat various coronaviruses (SARS-CoV-2, SARS-CoV, MERS-CoV, and common cold coronaviruses) simultaneously, providing broad-spectrum coverage that remdesivir cannot achieve alone.
Solution Approach 2:
The patent shifts the therapeutic target from viral components (as with remdesivir targeting viral RdRp) to a host factor (p97). This parameter change in target selection enables broad-spectrum activity against different coronavirus strains while maintaining mechanism of action through host cell machinery exploitation.
2Ease of operation
If current supportive therapies are used, then patient care is provided, but there is no effective antiviral treatment to inhibit infection and replication
Solution Approach 1:
The patent extracts and targets a specific host factor (p97) that is essential for viral replication but not directly involved in viral structure or entry. This extraction approach allows development of antivirals that disrupt replication without affecting viral components, providing effective treatment while maintaining safety.
Solution Approach 2:
p97 serves as an intermediary host protein that mediates viral replication by facilitating viral protein transport and assembly. By targeting this intermediary rather than direct viral components, the therapy achieves effective antiviral activity while avoiding direct viral interaction that could trigger immune responses.
3Reliability
If p97 inhibition is applied, then coronavirus replication is reduced and viral titers decrease, but the mechanism involves disrupting host cell machinery
Solution Approach 1:
The patent employs partial inhibition of p97 at concentrations sufficient to disrupt viral replication but below levels that cause severe host cell toxicity. This partial action approach maintains therapeutic efficacy while minimizing harmful effects on host cell functions.
Solution Approach 2:
The patent identifies and addresses potential host cell toxicity issues beforehand by selecting p97 inhibitors with selectiveivity for viral replication processes and by establishing safe dosage ranges through preclinical studies, thereby cushioning against harmful effects before they occur.
Data Source
AI summary
Provided herein are methods and compositions for inhibiting p97, for the treatment of a coronavirus infection in a subject, or a symptom thereof. Upon treatment, the coronavirus infection, or a symptom thereof is reduced in the subject.